Inhibikase Therapeutics Reports $13.7M Net Loss in Q1 2025, EPS at $0.15

Reuters
05-15
Inhibikase <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports $13.7M Net Loss in Q1 2025, EPS at $0.15

Inhibikase Therapeutics Inc. reported its financial results for the first quarter ending March 31, 2025, showcasing a significant increase in net loss compared to the previous year. The company reported a net loss of $13.7 million for the quarter, which is a considerable increase from the $4.6 million net loss in the same period in 2024. Research and development expenses also rose sharply to $10.5 million from $2.8 million in the previous year, largely due to a $7.4 million non-cash charge related to the acquisition of CorHepta. The company's selling, general, and administrative expenses increased to $5.2 million from $2.0 million in 2024. As of March 31, 2025, Inhibikase had $93.2 million in cash, cash equivalents, and marketable securities. In business developments, the company has been advancing its lead candidate, IKT-001, into a late-stage clinical trial program for pulmonary arterial hypertension (PAH). The company is preparing to finalize the study design for a Phase 2b clinical study of IKT-001 in PAH and expects to initiate this study in the second half of 2025. The company recently appointed several key executives, including a new CEO, President and Head of Research & Development, Chief Scientific Officer, and Chief Financial Officer, to strengthen its leadership team.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451720-en) on May 14, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10